Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer-Reference-Cited by-同舟云学术

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Published:2010-01 Issue:1 Volume:21 Page:48-54
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mavroudis D.,Papakotoulas P.,Ardavanis A.,Syrigos K.,Kakolyris S.,Ziras N.,Kouroussis C.,Malamos N.,Polyzos A.,Christophyllakis C.,Kentepozidis N.,Georgoulias V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/1/48/340993/mdp498.pdf

Reference21 articles.

1. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials;De Laurentiis;J Clin Oncol,2008

2. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial;Pacilio;Br J Cancer,2006

3. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG);Kouroussis;Ann Oncol,1999

4. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study;Mavroudis;Ann Oncol,2000

5. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer;Bonneterre;Br J Cancer,2004

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis;Journal of Cancer Research and Clinical Oncology;2023-10-27

2. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial;npj Breast Cancer;2022-09-20

3. Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials;Future Oncology;2021-12

4. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer;Cochrane Database of Systematic Reviews;2021-05-26

5. Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version);Translational Breast Cancer Research;2020-10